There were no discontinuations because PF-562271 datasheet of nervous system events in the etravirine group (vs. 0.5% in the placebo group) and a very low frequency of discontinuations because of psychiatric events in both the etravirine and placebo treatment groups (0.3% and 0.2%, respectively). The frequency of grade 3 or 4 nervous system AEs of interest was low and comparable between the treatment groups, and similar proportions of patients reported grade 3 or 4 psychiatric events of interest (Table 1). By preferred term, and regardless of severity or causality, the most common nervous system events

of interest were headache, dizziness and somnolence, and the most common psychiatric events of interest were depression, insomnia and anxiety, each of which occurred in the etravirine

group at a rate similar to that in the placebo group (Table 1). Most neuropsychiatric events of interest occurred early during treatment (Fig. 1). A previous history of psychiatric disorders was found to increase the occurrence of nervous Akt inhibitor system and psychiatric AEs of interest in both treatment groups (P < 0.0001 and 0.0728 in the etravirine and placebo groups, respectively). Of those patients with a psychiatric history [46.7% (n = 280) and 43.9% (n = 265) in the etravirine and placebo groups, respectively], the overall frequency of neuropsychiatric events of interest was 42.1% and 40.0% in the etravirine and placebo groups, respectively; in patients with no psychiatric history, the corresponding frequencies were 26.3% and 32.7%, respectively. Regardless of severity or causality and consistent with previous findings at weeks 24 and 48, rash occurred at a significantly higher frequency

in the etravirine arm than in the placebo arm (20.5% vs. 11.8%, respectively; 95% CI 4.6–12.9; P < 0.0001, Fisher's exact test; predefined analysis) (Table 2). Most cases of rash occurred within the first 2 weeks of treatment and resolved with continued treatment; the frequency of rash occurring after 48 weeks was low. Discontinuation selleck chemicals llc because of rash was infrequent in the etravirine group (2.2%, all of which occurred in the first 48 weeks of treatment) and there were no discontinuations because of rash in the placebo group. The majority of rash events were grade 1 or 2 in severity (Table 2). One patient in the placebo group developed a grade 4 vesicular rash in the first 48 weeks (Stevens–Johnson syndrome), thought to be related to an allergic reaction to trimethoprim/sulfamethoxazole; no other grade 4 rashes were reported. There were no clear differences between the treatment groups for different individual types of rash apart from general rash (Table 2). A significantly higher proportion of women than men in the etravirine group reported rash [31.7% (n = 19) vs. 19.3% (n = 104), respectively; P = 0.